Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $1,175,400.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John E. Kao sold 90,000 shares of Alignment Healthcare stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $13.06, for a total transaction of $1,175,400.00. Following the sale, the chief executive officer now directly owns 2,273,100 shares of the company's stock, valued at $29,686,686. This represents a 3.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Alignment Healthcare Stock Performance

Shares of NASDAQ:ALHC traded up $1.62 on Monday, reaching $13.50. The company's stock had a trading volume of 4,890,529 shares, compared to its average volume of 1,764,946. Alignment Healthcare, Inc. has a 52-week low of $4.46 and a 52-week high of $14.25. The stock has a market capitalization of $2.59 billion, a P/E ratio of -17.53 and a beta of 1.45. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The stock's 50-day moving average is $11.91 and its two-hundred day moving average is $10.58.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Alignment Healthcare had a negative return on equity of 108.69% and a negative net margin of 5.84%. The business had revenue of $692.43 million for the quarter, compared to analysts' expectations of $662.11 million. During the same quarter last year, the firm earned ($0.19) earnings per share. The business's revenue was up 51.6% on a year-over-year basis. As a group, sell-side analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Alignment Healthcare

Large investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. Series C boosted its holdings in Alignment Healthcare by 31.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company's stock valued at $85,250,000 after acquiring an additional 2,630,788 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Alignment Healthcare by 94.4% during the 2nd quarter. William Blair Investment Management LLC now owns 3,104,681 shares of the company's stock valued at $24,279,000 after acquiring an additional 1,507,759 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Alignment Healthcare during the third quarter worth about $3,782,000. Renaissance Technologies LLC lifted its stake in shares of Alignment Healthcare by 16.8% during the second quarter. Renaissance Technologies LLC now owns 1,565,800 shares of the company's stock worth $12,245,000 after purchasing an additional 225,000 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Alignment Healthcare by 249.3% in the third quarter. JPMorgan Chase & Co. now owns 288,219 shares of the company's stock worth $3,407,000 after buying an additional 205,705 shares during the period. Hedge funds and other institutional investors own 86.19% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ALHC shares. Stephens reiterated an "overweight" rating and issued a $17.00 target price on shares of Alignment Healthcare in a report on Thursday, January 2nd. UBS Group increased their price target on shares of Alignment Healthcare from $9.00 to $12.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Barclays raised their target price on Alignment Healthcare from $7.00 to $8.00 and gave the stock an "underweight" rating in a report on Wednesday, October 30th. Finally, KeyCorp initiated coverage on Alignment Healthcare in a report on Friday, October 11th. They issued a "sector weight" rating on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Alignment Healthcare presently has a consensus rating of "Moderate Buy" and an average price target of $11.38.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.